Logo

CDIO

Cardio Diagnostics Holdings, Inc.

CDIO

Cardio Diagnostics Holdings, Inc. • NASDAQ
$2.88 ▼ -2.04% (-0.06)
Market Cap $5.26 M
52w High $53.10
52w Low $2.42
Dividend Yield 0%
P/E -0.24
Volume 9.42K
Outstanding Shares 1.83M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.855K ▼ $1.625M ▲ $-1.715M ▼ -60.054K% ▼ $-0.98 ▼ $-1.622M ▼
Q2-2025 $7.475K ▲ $1.597M ▼ $-1.683M ▼ -22.518K% ▲ $-0.97 $-1.589M ▼
Q1-2025 $940 ▼ $1.631M ▲ $-1.635M ▼ -173.943K% ▼ $-0.97 ▼ $-1.505M ▼
Q4-2024 $4.512K ▼ $1.521M ▲ $-1.519M ▼ -33.673K% ▼ $-0.062 ▲ $-1.432M ▼
Q3-2024 $6.58K $1.416M $-1.413M -21.468K% $-1.73 $-1.326M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $6.355M ▼ $8.789M ▼ $637.331K ▼ $8.152M ▼
Q2-2025 $7.966M ▼ $10.397M ▼ $671.848K ▼ $9.725M ▼
Q1-2025 $9.689M ▲ $12.282M ▲ $904.998K ▼ $11.377M ▲
Q4-2024 $7.827M ▲ $10.615M ▲ $1.058M ▲ $9.558M ▲
Q3-2024 $1.983M $4.481M $795.276K $3.686M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.715M ▼ $-1.393M ▲ $-257.819K ▼ $39.955K ▲ $-1.611M ▲ $-1.556M ▲
Q2-2025 $-1.683M ▼ $-1.571M ▼ $-35.717K ▲ $-115.037K ▼ $-1.722M ▼ $-1.59M ▼
Q1-2025 $-1.635M ▼ $-1.4M ▼ $-47.415K ▲ $3.309M ▼ $1.861M ▼ $-1.448M ▼
Q4-2024 $-1.519M ▼ $-1.392M ▼ $-54.613K ▲ $7.292M ▲ $5.845M ▲ $-1.396M ▼
Q3-2024 $-1.413M $-1.157M $-78.567K $1.908M $672.471K $-1.181M

Five-Year Company Overview

Income Statement

Income Statement Cardio Diagnostics is still essentially a pre‑revenue company. Over the past several years it has not generated meaningful sales, and its reported activity reflects early-stage development rather than a mature operating business. The company runs at a loss, which is typical for a young biotech focused on building and validating technology before broad commercialization. Earnings per share look very volatile and deeply negative, but this is largely influenced by changes in share count and capital structure rather than big swings in the underlying business. Overall, the income statement shows an R&D‑driven, cash‑burning platform that has not yet converted its science into recurring revenue.

Balance Sheet

Balance Sheet The balance sheet is very light. Assets are minimal and mostly consist of a small cash position, with little in the way of physical assets or inventories. Equity is similarly small, reflecting the early stage of the company and its limited capital base. On the positive side, there is no reported debt, so the company is not burdened by interest payments. On the risk side, the very small asset and equity base suggests only a thin financial cushion. The recent reverse stock split also signals that the company has had to manage a very low share price, which often goes hand‑in‑hand with capital and dilution pressures.

Cash Flow

Cash Flow Cash flows show a business that is consuming, not generating, cash. Operating cash flow has been steadily negative, reflecting ongoing spending on research, development, and overhead without any offsetting revenue stream. Free cash flow is also negative, though the company is not investing heavily in physical assets, so the drain is mainly from operating expenses. This pattern is common in early-stage biotech, but it means the company is likely reliant on raising new capital over time to fund operations. Any delays in scientific, regulatory, or commercial milestones increase financing risk.

Competitive Edge

Competitive Edge Cardio Diagnostics is trying to build a niche in cardiovascular diagnostics by combining AI with genetic and epigenetic markers, which is a newer and more specialized approach than traditional tests. This gives it a differentiated scientific story and some first‑mover advantages in its chosen segment. Its competitive moat is being built around proprietary algorithms, biomarker panels, and an expanding patent portfolio across major markets. Partnerships with hospitals, clinicians, and research groups help validate the technology and may support adoption. However, the company is still very small and will face competition from much larger diagnostics and medtech players with deeper pockets, broader sales forces, and established reimbursement relationships. Execution in commercialization and payer coverage will be critical.

Innovation and R&D

Innovation and R&D Innovation is the clear strength of Cardio Diagnostics. Its core platform integrates genetic and epigenetic data with AI to assess heart disease risk and presence, potentially offering more precise and personalized insights than conventional tools. The company already has two focused products for coronary heart disease and is building supporting software that turns test results into more actionable insights for clinicians. It is also positioning its platform for use by pharmaceutical companies in research and clinical trials. Looking ahead, management aims to extend the same engine to other cardiovascular conditions and to keep improving accuracy through new biomarkers and algorithms. The opportunity is meaningful if the tests prove clinically valuable and cost‑effective in real‑world practice. At the same time, this is a high‑uncertainty path: clinical validation, regulatory dynamics, physician adoption, and payer acceptance all need to line up for the R&D investment to pay off.

Summary

Cardio Diagnostics is an early-stage, science‑heavy healthcare company with virtually no revenue to date and a very small financial base. The business today is defined far more by its technology platform and clinical development efforts than by traditional financial performance. Financially, it operates with thin resources, no debt, and ongoing cash burn, which makes continued access to external capital a central issue. Operationally, the company is trying to pioneer AI‑driven genetic‑epigenetic diagnostics for heart disease, supported by patents, specialized tests, and growing partnerships. The story is one of high potential and high uncertainty. The long‑term outcome will depend on whether the company can: (1) conclusively demonstrate clinical and economic value, (2) secure reimbursement and broad clinical adoption, and (3) finance itself through this journey without excessive strain. Until then, the profile remains that of a pre‑commercial biotech platform rather than a steady operating business.

NEWS

November 5, 2025 · 8:35 AM UTC

Cardio Diagnostics Holdings, Inc. to Present Data Demonstrating PrecisionCHD's Ability to Detect INOCA and MINOCA at the American Heart Association Scientific Sessions

Read more

October 28, 2025 · 8:35 AM UTC

Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community

Read more

October 21, 2025 · 8:35 AM UTC

Cardio Diagnostics Holdings, Inc. Expands Provider Network, Adding 15 New Provider Organizations From Across the United States

Read more